Sanofi $SNY Shares Purchased by NewEdge Advisors LLC

Posted by on Aug 13th, 2026

NewEdge Advisors LLC grew its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 18.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 77,501 shares of the company’s stock after buying an additional 12,172 shares during the period. NewEdge Advisors LLC’s holdings in Sanofi were worth $3,734,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Western Wealth Management LLC purchased a new stake in Sanofi during the 1st quarter worth about $29,000. Paragon Private Wealth Management LLC lifted its holdings in Sanofi by 81.6% in the 1st quarter. Paragon Private Wealth Management LLC now owns 8,802 shares of the company’s stock valued at $424,000 after purchasing an additional 3,955 shares in the last quarter. Bank of America Corp DE lifted its holdings in Sanofi by 11.0% in the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock valued at $456,956,000 after purchasing an additional 940,342 shares in the last quarter. Strategic Investment Advisors MI acquired a new stake in shares of Sanofi during the 1st quarter worth about $1,398,000. Finally, Arkadios Wealth Advisors boosted its stake in shares of Sanofi by 0.9% during the 1st quarter. Arkadios Wealth Advisors now owns 36,146 shares of the company’s stock worth $1,742,000 after purchasing an additional 315 shares during the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Shares of SNY stock opened at $43.71 on Thursday. Sanofi has a one year low of $40.89 and a one year high of $52.68. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The company has a 50 day moving average price of $43.36 and a 200 day moving average price of $44.99. The firm has a market capitalization of $105.97 billion, a price-to-earnings ratio of 22.88, a price-to-earnings-growth ratio of 1.09 and a beta of 0.35.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of analyst reports. Weiss Ratings lowered shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Wall Street Zen downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Sunday. Morgan Stanley set a $49.00 price target on Sanofi in a research note on Wednesday, July 8th. Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Finally, BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $49.50.

Check Out Our Latest Report on Sanofi

Sanofi Profile

(Free Report)

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

Read More

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.